IL1B and Cognitive impairment: In another study, Madecassoside was evaluated in an in vivo model for its potential in lipopolysaccharide-induced cognitive impairment and neuroinflammation, revealing that treatment for 14 days with 120 mg/kg reduced neurotoxicity, cognitive impairments and the production of inflammatory cytokine agents such as IL-1β, TNF-α, and IL-6 by a mechanism of activation of Nrf2 signaling [141].